19 May 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, announces the issue of 1,276,707 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.
Share Options were granted as follows:
| Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital | Effective Grant date |
| Peter Keeling, CEO | 102,468 | 435,313 | 0.52% | 18 May 2023 |
| Nick Roberts, CFO | 67,034 | 158,872 | 0.19% | 18 May 2023 |
| Ryan Keeling, CIO | 93,407 | 409,851 | 0.49% | 18 May 2023 |
| Julie Browne, COO and PDMR | 67,109 | 169,047 | 0.20% | 18 May 2023 |
| Jordan Clark, CCO and PDMR | 65,245 | 115,740 | 0.14% | 18 May 2023 |
| Susanne Munksted, CPO and PDMR | 68,834 | 249,199 | 0.30% | 18 May 2023 |
| Other employees (43 persons) | 812,610 | 1,675,537 | 1.98% | 18 May 2023 |
The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth in the proportion of subscription revenue and Total Shareholder Return ("TSR") during the Performance Period. The growth in TSR will be measured against a base share price of 103.97p, being the average mid-market closing share price in the three days prior to 18 May 2023. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.
Following this grant, the total number of share options outstanding in the Company is 3,826,487 representing approximately 4.52% of its current issued share capital of 84,461,386.
Enquiries:
| Diaceutics PLC | |
| Peter Keeling, Chief Executive Officer | Via Alma PR |
| Nick Roberts, Chief Financial Officer | |
| | |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison, Nick Harland, Nick Adams | |
| | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde, Kieran Breheny, Matthew Young | diaceutics@almapr.co.uk |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real‐world healthcare data insights, advisory services and innovative platform enabled solutions.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Peter Keeling | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Executive Officer, Director | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) | | | | | | |
| | Price(s) | Volume(s) | | ||||
| Exercise price of 0.2p per share | 102,468 | | |||||
| | |||||||
| e. | Date of the transaction | 18 May 2023 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Nick Roberts | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Finance Officer, Director | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) | | | | | | |
| | Price(s) | Volume(s) | | ||||
| Exercise price of 0.2p per share | 67,034 | | |||||
| | |||||||
| e. | Date of the transaction | 18 May 2023 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Ryan Keeling | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Innovation Officer, Director | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) | | | | | | |
| | Price(s) | Volume(s) | | ||||
| Exercise price of 0.2p per share | 93,407 | | |||||
| | |||||||
| e. | Date of the transaction | 18 May 2023 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Julie Browne | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Operations Officer and PDMR | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) | | | | | | |
| | Price(s) | Volume(s) | | ||||
| Exercise price of 0.2p per share | 67,109 | | |||||
| | |||||||
| e. | Date of the transaction | 18 May 2023 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Jordan Clark | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Commercial Officer and PDMR | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) | | | | | | |
| | Price(s) | Volume(s) | | ||||
| Exercise price of 0.2p per share | 65,245 | | |||||
| | |||||||
| e. | Date of the transaction | 18 May 2023 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Susanne Munksted | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Precision Medicine Officer and PDMR | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) | | | | | | |
| | Price(s) | Volume(s) | | ||||
| Exercise price of 0.2p per share | 68,834 | | |||||
| | |||||||
| e. | Date of the transaction | 18 May 2023 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
